Skip Navigation

Food Allergy

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

Guidelines for the Diagnosis and Management of Food Allergy in the United States

Financial and Other Disclosures

On this page:

How Are Conflicts of Interest Managed?

The disclosure and management of real, perceived, or potential financial conflicts of interest are a critical step in building public trust in clinical guidelines. To that end, NIAID established a procedure to ensure maximum transparency of the guidelines development process by reporting the affiliations and activities of members of the expert panel and representatives on the coordinating committee. Prospective members of the writing and review groups submitted written Conflict of Interest/Financial Disclosure Statements to an internal NIAID review panel considering their nomination and acceptance. Scientific and clinical expertise remained the paramount criteria for selection.

In addition to the public disclosure of this information, expert panel members verbally disclosed potential conflicts of interest to each other during their first general meeting and were asked to keep NIAID updated with any changes throughout the process. Panel members with conflicts of interest were requested to recuse themselves from voting on decisions relevant to the conflicted topic.

back to top

Expert Panel Members' Financial Disclosures

  • Dr. Arshad has received funding/grant support from National Institutes of Health (NIH) and the National Institute of Health Research, United Kingdom.
  • Dr. Assa’ad holds or is listed as an inventor on U.S. patent application #10/566903, titled “Genetic markers of food allergy.” She has served as a consultant for GlaxoSmithKline and as a speaker for the American College of Allergy, Asthma & Immunology; the North East Allergy Society; the Virginia Allergy Society; the New England Allergy Society; and the American Academy of Pediatrics. Dr. Assa’ad has received funding/grant support from GlaxoSmithKline.
  • Dr. Bahna has received funding/grant support from Genentech.
  • Dr. Beck has received funding/grant support from the American Academy of Allergy, Asthma & Immunology, the National Eczema Association, and NIH.
  • Dr. Boyce has served on the advisory board of GlaxoSmithKline. He has served as a consultant and/or speaker for Altana, GlaxoSmithKline, and Merck. He has received funding/grant support from NIH.
  • Dr. Burks holds or is listed as an inventor on multiple U.S. patents related to food allergy. He owns stock in Allertein and MastCell, Inc., and is a minority stockholder in Dannon Co. Probiotics. He has served as a consultant for ActoGeniX NV, McNeil Nutritionals, Mead Johnson, and Novartis. He has served on the speaker’s bureau for EpiPen/Dey, L.P., and has served on the data monitoring committee for Genentech. He has served on an expert panel for Nutricia. Dr. Burks has received funding/grant support from the Food Allergy and Anaphylaxis Network, Gerber, Mead Johnson, and NIH.
  • Dr. Byrd-Bredbenner owns stock in Johnson & Johnson. She has received funding/grant support from the U.S. Department of Agriculture (USDA), the Canned Food Alliance, and the New Jersey Department of Health and Senior Services.
  • Dr. Camargo has consulted for Dey and Novartis. He has received funding/grant support from a variety of government agencies and not-for-profit research foundations, as well as Dey and Novartis.
  • Dr. Eichenfield has received funding/grant support from a variety of not-for-profit foundations, as well as Astellas, Ferndale, Johnson & Johnson, Novartis, Sinclair, Stiefel, and Therapeutics Inc.
  • Dr. Furuta has served as a consultant and/or speaker to Ception Therapeutics and TAP. He has received funding/grant support from the American Gastrointestinal Association and NIH.
  • Dr. Hanifin has served as served as a consultant for ALZA; Anesiva, Inc.; Barrier Therapeutics, Inc.; Milliken & Company; Nordic Biotech; Novartis Pharmaceuticals Corporation; Shionogi USA; Taisho Pharmaceutical R&D, Inc.; Teikoku Pharma USA, Inc.; UCB; York Pharma; ZARS, Inc.; and ZymoGenetics. He has served as an investigator or received research funding from ALZA; Astellas Pharma US, Inc.; Asubio Pharmaceuticals, Inc.; Centocor, Inc.; Corgentech; Novartis; Nucryst Pharmaceuticals; Seattle Genetics; and Shionogi USA.
  • Ms. Carol Jones has no relevant financial interests.
  • Dr. Stacie Jones has served as a speaker and grant reviewer and has served on the medical advisory committee for the Food Allergy and Anaphylaxis Network. She has received funding/grant support from Dyax Corp, the Food Allergy and Anaphylaxis Network, Mead Johnson, the National Peanut Board, and NIH.
  • Dr. Kraft has served as a consultant and/or speaker for Astra-Zeneca, Genentech, GlaxoSmithKline, Merck, Novartis, and Sepracor. She has received funding/grant support from Genentech, GlaxoSmithKline, NIH, and Novartis.
  • Dr. Levy holds or is listed as an inventor on U.S. patent applications #20080064746, titled "Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases," and #20080096961, titled "Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma." He owns stock in Resolvyx Pharmaceuticals. He has served as a consultant for Bayer Healthcare and Resolvyx Pharmaceuticals. Dr. Levy has received funding/grant support from NIH.
  • Dr. Liacouras has served as a consultant and/or speaker to AstraZeneca, Merck, Nutrica, TAP, and Wyeth. He holds stock in Ception Therapeutics.
  • Dr. Lieberman has served as a consultant and/or speaker to Dey Laboratories, Novartis, Schering-Plough, AstraZenica, Merck, TEVA, Pfizer, MEDA, Alcon, Genentech, Intelliject, and the Food Allergy and Anaphylaxis Network. He is past president of the American Academy of Allergy, Asthma & Immunology.
  • Dr. Luccioli has no relevant financial interests.
  • Ms. McCall has no relevant financial interests.
  • Dr. Sampson holds or is listed as an inventor on multiple U.S. patents related to food allergy. He owns stock in Allertein Therapeutics. He is the immediate past president of the American Academy of Allergy, Asthma & Immunology. He has served as a consultant for Allertein Therapeutics, the American Academy of Allergy, Asthma & Immunology, the Food Allergy Initiative, and Schering Plough. He has received funding/grant support for research projects from the Food Allergy Initiative, NIH (DRR, NIAID, NCCAMS), and Phadia AB. He is a co-owner of Herbal Spring, LLC.
  • Dr. Schneider has served as a consultant/clinical advisor for the Food Allergy Initiative. She has received funding/grant support from a variety of not-for-profit research foundations, as well as Novartis and NIH.
  • Dr. Ronald Simon has served as a speaker for Dey Laboratories, Genentech, GlaxoSmithKline, Merck, Novartis, and the Food and Drug Administration.
  • Dr. Estelle Simons holds a patent on “Fast-disintegrating epinephrine tablets for sublingual administration.” She is a past-president of the American Academy of Allergy, Asthma & Immunology and of the Canadian Society of Allergy & Clinical Immunology. She is a member of the advisory boards of Dey, Intelliject, and ALK-Abello. She has received funding/grant support from AllerGen, the Canadian Allergy, Asthma and Immunology Foundation/Anaphylaxis Canada, and the Canadian Institutes of Health Research.
  • Dr. Teach has served as a speaker for AstraZeneca. He has received funding/grant support from the AstraZeneca Foundation, Aventis, the Child Health Center Board, the CNMC Research Advisory Council, the National Association of Chain Drug Stores Foundation, NIH (NIAID, NHLBI), Novartis/Genentech, the Robert Woods Johnson Foundation, the Centers for Disease Control and Prevention, the U.S. Public Health Service, and the Washington, D.C., Department of Health.
  • Dr. Wood has served as a speaker/advisory board member for GlaxoSmithKline, Merck, and Dey. He has received funding/grant support from Genentech and the NIH (NIAID).
  • Dr. Yawn has no relevant financial interests.

back to top

Coordinating Committee Representatives' Financial Disclosures

  • Dr. Bahna has received funding/grant support from Genentech.
  • Dr. Bergman has no relevant financial interests.
  • Ms. Block has no relevant financial interests.
  • Ms. Book has no relevant financial interests.
  • Dr. Bradsher has no relevant financial interests.
  • Dr. Brasler has no relevant financial interests.
  • Dr. Czinn has no relevant financial interests.
  • Dr. Decker has no relevant financial interests.
  • Dr. Eichenfield has received funding/grant support from a variety of not-for-profit foundations, as well as Astellas, Ferndale, Johnson & Johnson, Novartis, Sinclair, Stiefel, and Therapeutics Inc.
  • Ms. Finch has no relevant financial interests.
  • Dr. Fuchs is an executive board member for the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition.
  • Ms. Heller has no relevant financial interests.
  • Dr. Huss has no relevant financial interests.
  • Dr. Kline holds or is listed as an inventor on U.S. patents #6,207,646, #6,239,116, and #20,030,050,261 on “Immunostimulatory nucleic acid molecules.” He has served on the speaker bureaus for GlaxoSmithKline, Novartis, Genentech, and Astra-Zeneca. Dr. Kline has received funding/grant support from Genentech/Novartis, GlaxoSmithKline and Schering-Plough.
  • Ms. Mays has no relevant financial interests.
  • Ms. McCall has no relevant financial interests.
  • Dr. Muraro has no relevant financial interests.
  • Mr. Pacenza has no relevant financial interests.
  • Dr. Papadopoulos has no relevant financial interests.
  • Dr. Sampson holds or is listed as an inventor on multiple U.S. patents related to food allergy. He owns stock in Allertein Therapeutics. He is the immediate past president of the American Academy of Allergy, Asthma & Immunology. He has served as a consultant for Allertein Therapeutics; the American Academy of Allergy, Asthma & Immunology; the Food Allergy Initiative; and Schering-Plough. He has received funding/grant support for research projects from the Food Allergy Initiative, NIH (DRR, NIAID, NCCAMS), and Phadia AB. He is a co-owner of Herbal Spring, LLC.
  • Dr. Sicherer has served as a medical consultant for the Food Allergy Initiative. He has received funding/grant support for research projects from the Food Allergy and Anaphylaxis Network, the Food Allergy Initiative, NIH, and USDA.
  • Ms. Smith Edge has no relevant financial interests.
  • Dr. J. Wood has served as a speaker for Sonoran Ultrasound LLC.

back to top

Last Updated November 16, 2010

Last Reviewed October 01, 2010